Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.
Garrett N, Reddy T, Yende-Zuma N, Takalani A, Woeber K, Bodenstein A, Jonas P, Engelbrecht I, Jassat W, Moultrie H, Bradshaw D, Seocharan I, Odhiambo J, Khuto K, Richardson SI, Omondi MA, Nesamari R, Keeton RS, Riou C, Moyo-Gwete T, Innes C, Zwane Z, Mngadi K, Brumskine W, Naicker N, Potloane D, Badal-Faesen S, Innes S, Barnabas S, Lombaard J, Gill K, Nchabeleng M, Snyman E, Petrick F, Spooner E, Naidoo L, Kalonji D, Naicker V, Singh N, Maboa R, Mda P, Malan D, Nana A, Malahleha M, Kotze P, Allagappen JJ, Diacon AH, Kruger GM, Patel F, Moore PL, Burgers WA, Anteyi K, Leav B, Bekker LG, Gray GE, Goga A; SHERPA study team. Garrett N, et al. Among authors: yende zuma n. PLOS Glob Public Health. 2024 Dec 5;4(12):e0003260. doi: 10.1371/journal.pgph.0003260. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39636838 Free PMC article.
SARS-CoV-2 seropositivity in African women living with HIV and their infants.
Matubu TA, Yende-Zuma N, Brummel SS, Stranix-Chibanda L, Ogwang LW, Dadabhai S, Atuhaire P, Chauwa F, Gadama L, Fernandez RE, Aizire J, Jackson J, Tobian AAR, Taha TE, Fowler MG. Matubu TA, et al. Among authors: yende zuma n. BMC Infect Dis. 2024 Jul 11;24(1):693. doi: 10.1186/s12879-024-09591-8. BMC Infect Dis. 2024. PMID: 38992577 Free PMC article.
Unintended pregnancy and contraception use among African women living with HIV: Baseline analysis of the multi-country US PEPFAR PROMOTE cohort.
Aizire J, Yende-Zuma N, Hanley S, Nematadzira T, Nyati MM, Dadabhai S, Chinula L, Nakaye C, Fowler MG, Taha T; US-PEPFAR PROMOTE Cohort Study team. Aizire J, et al. Among authors: yende zuma n. PLoS One. 2024 Mar 11;19(3):e0290285. doi: 10.1371/journal.pone.0290285. eCollection 2024. PLoS One. 2024. PMID: 38466748 Free PMC article.
Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
Takalani A, Robinson M, Jonas P, Bodenstein A, Sambo V, Jacobson B, Louw V, Opie J, Peter J, Rowji P, Seocharan I, Reddy T, Yende-Zuma N, Khutho K, Sanne I, Bekker LG, Gray G, Garrett N, Goga A; Sisonke Study Team. Takalani A, et al. Among authors: yende zuma n. Vaccine. 2024 Feb 27;42(6):1195-1199. doi: 10.1016/j.vaccine.2024.01.066. Epub 2024 Jan 25. Vaccine. 2024. PMID: 38278629 Clinical Trial.
Breastfeeding Among Women Living With HIV in the Era of Lifelong ART: An Observational Multicountry Study in Eastern and Southern Africa.
Taha TE, Bandala-Jacques A, Yende-Zuma N, Violari A, Stranix-Chibanda L, Atuhaire P, Hanley S, Gadama L, Chinula L, Dadabhai S, Aizire J, Brummel SS, Fowler MG. Taha TE, et al. Among authors: yende zuma n. J Acquir Immune Defic Syndr. 2024 Jan 1;95(1):10-17. doi: 10.1097/QAI.0000000000003306. J Acquir Immune Defic Syndr. 2024. PMID: 37732877 Clinical Trial.
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
Mahomed S, Garrett N, Capparelli EV, Osman F, Mkhize NN, Harkoo I, Gengiah TN, Mansoor LE, Baxter C, Archary D, Yende-Zuma N, Samsunder N, Carlton K, Narpala S, McDermott AB, Doria-Rose NA, Moore PL, Morris L, Abdool Karim Q, Mascola JR, Abdool Karim SS. Mahomed S, et al. Among authors: yende zuma n. Lancet HIV. 2023 Apr;10(4):e230-e243. doi: 10.1016/S2352-3018(23)00003-6. Lancet HIV. 2023. PMID: 37001964 Clinical Trial.
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial.
Naidoo A, Dooley KE, Naidoo K, Padayatchi N, Yende-Zuma N, Perumal R, Dorse G, Boodhram R, Osuala EC. Naidoo A, et al. Among authors: yende zuma n. BMJ Open. 2022 Nov 10;12(11):e067765. doi: 10.1136/bmjopen-2022-067765. BMJ Open. 2022. PMID: 36356989 Free PMC article. Clinical Trial.
79 results